GlassScriptPhysician profile
Donald Lazas
NPI 1427055326
$3,147.82
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $439 · 2021: $90.40 · 2022: $278 · 2023: $2,203 · 2024: $31.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,100 · Food and Beverage: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,100.00 |
| Food and Beverage | $133.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,100.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $357.53 | 2020 | |
| Abbvie INC. | $172.58 | 2019-2023 | |
| Celgene Corporation | $112.67 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $102.82 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $63.94 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.41 | 2020-2023 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $46.62 | 2019-2020 | |
| Baxter Healthcare | $33.76 | 2022 | |
| Organon LLC | $23.09 | 2022 | |
| Medtronic, INC. | $19.57 | 2023 | Gi Genius |
| Fresenius Kabi USA, LLC | $18.06 | 2023 | |
| Qol Medical, LLC | $16.75 | 2023 | Sucraid |
| Pfizer INC. | $15.79 | 2022 | |
| Intercept Pharmaceuticals, INC. | $14.23 | 2023 | Ocaliva |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Lazas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.